According to Goldman Sachs, Amgen AMGN Sell rating is maintained.
Goldman Sachs said that is sees prostate cancer as an attractive strategic opportunity. “Our Sell rating and $50, 12-month DCF-derived price target are unchanged.”
Amgen closed yesterday at $57.62.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in